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Abstract
Nonsteroidal anti‐inflammatory drugs (NSAIDs) are commonly used as anti‐inflammatory 
and analgesic agents. This family of drugs suppresses prostaglandin synthesis through 
inhibition of cyclooxygenase (COX) enzymes. Recent studies displayed that anti‐carcino-
genic actions of these drugs are mediated by COX‐2 enzyme. Currently, there is intense 
research on COX‐2 inhibitors as therapeutic targets. Etodolac is not perfectly selective 
but shows ‘preferential selectivity’ for COX‐2. Here, in this study, we wanted to take 
gene expression snapshots of several apoptotic proteins under different conditions of 
drug exposure. The aim, therefore, focused to determine differential effects of etodolac 
on the regulation of apoptotic genes in hormone‐responsive MCF‐7 and triple‐negative 
MDA‐MB‐231 cancer cell lines. Our data suggest that MDA‐MB‐231 is more responsive 
to etodolac exposure. Cell proliferation and apoptosis consistently regulated upon drug 
addiction. Furthermore, COX‐2/HER2 was explicitly an up‐regulated, phosphorylated 
form of Bad accumulated and anti‐apoptotic proteins SAG and survivin increased in both 
transcriptional and translational levels. Changes in mitochondrial Bcl‐2 family proteins 
were moderate and pro‐ and anti‐apoptotic proteins showed similar levels of regulation 
in both cell lines. We believe that these findings would be supportive for future studies 
targeting etodolac‐based therapies, as it reveals apoptotic factors differentially regulated 
in hormone‐responsive and invasive cell lines.
Keywords: apoptosis, MCF‐7, MDA‐MB‐231, MTT, Bad, SAG
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
1. Introduction
Nonsteroidal anti‐inflammatory drugs (NSAIDs), regularly used for their anti‐inflammatory 
and analgesic effects, were shown to have potency for cancer prevention as well [1, 2]. This 
family of drugs suppresses prostaglandin synthesis through inhibition of cyclooxygenase 
(COX) enzymes. COX enzymes have two isoforms COX‐1 and COX‐2, with a recent addition 
of a splice variant of COX‐1, COX‐3, which is not functional in humans. COX‐1 is commonly 
expressed in body, showing constitutive activation. COX‐2, on the other hand, is hardly 
detectable in normal conditions but is induced upon stimulation by mitogenic agents, cyto-
kines, growth factors, and so on. Later reports, however, demonstrated that COX‐2 is also 
constitutively expressed in basal levels at several tissues including gastric mucosa, develop-
ing brain or kidney [3–5].
COX isoforms catalyse prostaglandin G/H (PGG2/PGH2) synthesis from arachidonic acid, 
and these prostaglandins are then converted to stable forms like PGD2, PGE2, PGF2, pros-
tacyclin (PGI2) or thromboxane A2 (TXA2) depending on the cell type. Inhibition of COX 
enzymes, therefore, could result in improper prostaglandin activity, which in turn may cause 
different side effects. Since COX‐1 was mostly expressed in gastrointestinal tract (GI), intesti-
nal side effects of NSAIDs were suggested to decline if selective COX‐2 inhibitors were used. 
A detailed discussion about the role of COX enzymes in GI damage can be found in a review 
by Lazzaroni et al. [6].
A wide range of COX‐2 inhibitors (coxibs) were introduced to the market. Soon after clini-
cal approval and usage, most of these drugs were withdrawn due to the emerging new side 
effects. Selective COX‐2 inhibition partly reduced GI‐related pathologies, but they were 
marked for their adverse effects in cardiovascular (CV) system. Regulation of blood coagu-
lation involves the action of COX enzymes: COX‐1 in platelets produces TXA2, and COX‐2 
in endothelial cells produces PGI2, achieving a balance between thrombotic/anti‐thrombotic 
activities [7]. Drugs targeting one of the enzymes specifically could alter this balance and can 
cause bleeding or thrombosis. In this context, prevalent COX isoform in vascular endothelium 
was also a point of debate and a recent report showed that it is the COX‐1, rather than COX‐2, 
that is responsible for prostacyclin release in these cells [8]. Altogether, these findings imply 
necessity of further work on the side effects of COX‐2 inhibitors.
Early reports about the role of NSAIDs in cancer were from the studies on colorectal cancer 
(CRC). Inducible form of COX enzymes, namely COX‐2, was found to be elevated in colorectal 
cancer patients and early polyp formations were preceded by COX‐2 induction [9]. Regular 
use of NSAIDs reportedly reduced CRC occurrence in 30–50%, mostly by COX inhibition, 
though later studies revealed that COX‐2 inhibitors could also act on COX‐independent path-
ways [2, 10]. These studies were further confirmed by many others and in different types of 
cancers like prostate, breast or lung cancers [11–13].
COX‐2 is the main form participating in PGE2 production. When its activity is suppressed, 
protein expression is up‐regulated [14]. Since there is strong evidence that COX‐2 expres-
sion‐related PGE2 increase acts on tumourigenesis and possible side effects could be reduced 
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by targeting molecular downstream effectors taking part in this pathway such as cell cycle 
regulation, inhibiting proliferation and inducing apoptosis.
Presented study summarizes current knowledge available on various coxib agents in molecu-
lar level. Besides, it focuses on the molecular effects of etodolac in cancer cells. As a part of our 
study, we are testing various etodolac derivatives synthesized by our collaborators. Etodolac 
has different structural characteristic than other coxibs, in that it has no sulphonyl, sulphon-
amide or sulphone groups to facilitate COX‐2 binding. Its toxicity and relative selectivity for 
COX‐2 are low, and although there are numerous studies about its anti‐cancerogenic activ-
ity, dose‐response relationship on various cancer cell lines and molecular downstream effec-
tors was not well documented. Here, we present our preliminary results on the expression 
changes of various apoptotic proteins between hormone responsive and nonresponsive breast 
cancer cell lines under different doses and points.
2. COX‐2 inhibitors and their biological effects
2.1. COX‐2 inhibitors (coxibs) in common use
Specific COX‐2 inhibitors rofecoxib and valdecoxib were withdrawn from the market due to 
their cardiovascular side effects [15]. Celecoxib, brand name Celebrex, presented to the mar-
ket by Pfizer, is still in use, with precaution for possible cardiovascular thrombotic events. In 
addition to its anti‐inflammatory and analgesic properties, celecoxib is also known to reduce 
premalignant adenomatous polyps and affects signalling pathways involved in malignant 
transformation in tumours, but not in normal tissues [16]. Celecoxib showed COX‐1/COX‐2 
ratio of 30 in IC50 values, meaning that it has 30 times more potency at inhibiting COX‐2 with 
respect to COX‐1. Rofecoxib, was introduced to the market at the same time, has nearly 272‐
fold potency in COX‐2 selectivity. This higher selectivity on COX‐2 inhibition resulted in more 
severe adverse effects of the drug, and its use was banned by Food and Drug Administration 
(FDA).
Etoricoxib is developed by Merck & Co. It is approved in many countries worldwide, with the 
exception of US. Selectivity of this drug for COX‐2 is nearly 100‐fold more than COX‐1 [17]. 
Parecoxib is another COX‐2 inhibitor drug introduced to the market. Since parecoxib is a pro‐
drug of valdecoxib, it has similar pharmacodynamic properties as valdecoxib, which have a 
COX‐1/COX‐2 IC50 ratio of around 60, 2–2.5‐fold higher than that of celecoxib, and it has no 
anti‐thrombotic activity. Both drugs were not approved by the Food and Drug Administration 
(FDA) yet, but they are available in Europe and many other countries. Lumiracoxib (Novartis 
AG) is one of the most selective COX‐2 inhibitors with significant reduction in gastrointestinal 
side effects [18]. Though it is being approved in more than 50 countries, it was not approved 
by FDA.
Several randomized clinical studies suggest that the novel coxibs have comparable efficacy to 
nonselective NSAIDs in the treatment of osteoarthritis, rheumatoid arthritis and acute pain, 
but they share similar renal side effects. The apparent dose dependence of renal toxicity may 
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limit the use of higher doses of the novel coxibs for improved efficacy. Large‐size randomized 
clinical trials are ongoing to define the gastrointestinal and cardiovascular safety of the novel 
coxibs.
Etodolac is one of the first NSAIDs approved by FDA. It has been grouped in family show-
ing ‘preferential selectivity’ for COX‐2 together with meloxicam and nimesulide [19]. It has 
approximately threefold higher selectivity for COX‐2, but full dose could be inhibitory for 
COX‐1, too.
2.2. COX‐2/PGE2 signalling pathway
To prevent adverse side effects of NSAIDs and to better describe their anti‐carcinogenic 
properties, it is important to clarify COX‐2‐related signalling pathways, especially on prolif-
eration, cell cycle and apoptosis. Since most of their anti‐carcinogenic effects are produced 
by COX‐2/PGE2 regulation, direct intervention with the downstream players could be a 
promising approach to reduce unwanted side effects.
Downstream targets of PGE2 are four different G‐protein‐coupled receptors (EP1, EP2, EP3 
and EP4) on the membrane, each initiating different signalling systems. The EP1 receptor is 
coupled to the Gαq protein subunit that activates phosphoinositide signalling through phos-
pholipase C (PLC). PLC hydrolyses phosphatidylinositol 4,5‐bisphosphate (PIP2) to generate 
the secondary messengers inositol 1,4,5‐triphosphate (IP3) and diacylglycerol (DAG) This sig-
nalling pathway regulates intracellular calcium through PLC/IP3 and activates protein kinase 
C (PKC) through DAG. Clinical observations do not support any strict correlation between 
EP1 and cancer. However, since the activation of PLC ultimately leads to the activation of 
PKC, gene transcription would be effected due to mitogen‐activated protein (MAP) kinase, 
nuclear factor‐kappaB (NFκB) or Bcl2/Bad pro‐apoptotic pathways [20–22]. EP1 was also 
shown to contribute to the development of UVB‐ or chemically induced skin cancers. UVB‐
induced squamous cell carcinomas display higher levels of EP1 expression than uninvolved 
skin [23]. Consistent with these conclusions is that the topical application of a selective EP1 
antagonist protects against UVB‐induced tumours [24].
While EP1 seems to have a secondary role in tumourigenesis, EP2‐EP4 receptors obviously 
effect major cancer‐signalling pathways. Secondary messenger systems like Gαs‐cAMP‐ERK 
signalling activated by EP2 or Ras/MAPK/ERK signalling activated by EP4 could affect cel-
lular functions like differentiation, cell survival, cell growth or proliferation and apopto-
sis. EP2 also works through PI3K/Akt system together with axin and APC, leading to the 
accumulation of unphosphorylated form of β‐catenin in the cytoplasm. The result would 
be a series of events initiated by transcription factors to yield cell proliferation, survival or 
angiogenesis [20].
A recent study reported interesting relation between PGE2 and insulin‐like growth factor 
(IGF‐1)/Akt/mTORC1‐signalling pathway in recovering effects of obesity in pancreatic cancer 
cells. The study reveals that PGE2‐stimulated mTORC1 activation occurs not through Akt but 
rather through cooperative action of EP4/cAMP/PKA and EP1/Ca2+ pathways [25].
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EP2 positively and EP3 negatively regulate adenylate cyclase mediated by heterotrimeric 
G‐proteins G‐alphas or G‐alphai, respectively. Resultant activation/deactivation of protein 
kinase A changes transcription factor activities of CREB and ERK1/2 through phosphoryla-
tion, which are correlated with phosphorylation of Bad or activation of cyclin D1, COX‐2 and 
VEGF, respectively.
EP4 leads to the activation of adenylate cyclase, cAMP formation, activation of MAPK signal-
ling, with an end point of CREB activation. This, in turn, causes the rise in Bcl‐2 levels and 
inhibition of p53‐induced apoptosis [26, 27].
2.3. Molecular pathway studies on coxibs
Etodolac‐induced apoptosis was studied in Burkitt's lymphoma cells, and it was shown that 
the induction is higher with respect to meloxicam, a drug classified in the ‘preferential selec-
tive’ COX‐2 inhibitors, such as etodolac [10]. In this study, the treatment of cell with 100 μM 
etodolac was sufficient to reduce Bcl‐2, Bcl‐xL, cIAP‐1 and survivin, and cleaved Procaspase‐9, 
‐3 and PARP in a dose‐dependent manner. Since these cells do not express COX‐2 enzyme, 
observed effects might be following a COX‐2‐independent pathway. Down‐regulation of 
Bcl‐2 was also reported in prostate cancer cell lines. In accordance with Kobayashi's report, 
there was no change in COX‐2 levels after etodolac treatment and growth inhibition was cor-
related with hormone sensitivity. On the other hand, induction of apoptosis by celecoxib did 
not show any hormone dependency and progressed through Akt regulation, instead of Bcl‐2 
[11, 28].
Bcl‐2, an antiapoptotic protein, prevents induction of apoptosis by sequestering BH‐3 only 
proteins like Bim, Bid, NOXA, PUMA, phosphorylated Bad or BNIP. These BH3‐only pro-
teins can either activate (directly or indirectly) Bax or Bak proteins, which are located at the 
mitochondrial outer membrane and change permeabilization or they inactivate anti‐apop-
totic Bcl‐2 family members [29]. When there is an apoptotic stimulus, BH3‐only proteins 
are up‐regulated and they can directly act on Bax and Bak, initiating cytochrome c release 
through VDAC (voltage‐dependent anion channel). In addition to direct activator BH‐3‐only 
proteins, sensitizer BH‐3 group, such as Bad, NOXA or BNIP3, can release activators from 
anti‐apoptotic BH1‐4 proteins and initiate apoptosis through an indirect pathway [30, 31]. 
PUMA, an activator of BH3 protein, and NOXA, a sensitizer, both are found to be expressed 
in a p53‐dependent manner.
Molecular studies to understand COX‐2 inhibitors’ action mostly concentrated on two spe-
cific coxibs, celecoxib and rofecoxib. In HT‐29 cells, celecoxib was found to reduce p38 and 
p55 MAPK phosphorylation, together with a reduction in adhesion molecules ICAM‐1 and 
VCAM‐1 [32]. Data indicated that there is an induction of pro‐apoptotic response (Bax and 
Bid) in a dose‐time‐dependent manner. Global transcription profiling in colon cancers implied 
modulations on the genes related to cell cycle and apoptosis, but these changes were mostly 
observed in both COX‐2 (+) and (‐) cell lines [33]. Celecoxib induces cell cycle arrest at G1‐
phase, together with decreases in the inhibition of various cyclin expressions. Celecoxib can 
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inhibit protein kinase B (PKB/Akt) or its upstream kinase phosphoinositide‐dependent kinase 
1 (PDK‐1) [34, 35]. Partial inhibition of PKB/Akt results in a relative activation of cell cycle 
inhibitors p21 and p27, which can cause the partial inactivation of cyclin‐CDK complexes. 
However, a detailed mechanism has not been elucidated, since there was no change in the 
expressions of p21 and p27, cyclins or in the phosphorylation of CDK complexes [36].
Cell cycle gene profiling was conducted in normal breast epithelial cells, where 96 genes in 
p53 pathway were studied under two different doses of etodolac (0.5 and 2 mM) for 48 h [37]. 
Prominent regulation was observed in ATM, CCND2 (Cyclin D2), CCNF (Cyclin F), CDC20 
(p55cdc), CDKIN1A (p21) and RAD50. Apoptotic protein BAX was found to be down‐regulated 
only after 2‐mM application.
3. Methods
3.1. Cell viability assay
Cell viability was determined using Cell Proliferation Kit I (MTT) (Roche) according to the 
manufacturer's instructions. Briefly, cells were seeded into 96‐well plates (104 cells/well) and 
incubated at 37°C in CO2 incubator for 24 h. The next day, appropriate doses of drug were added and cells were further incubated for 24 or 48 h. MTT of 10 μL was added to each well 
for an additional 4 h. The precipitated formazan was dissolved in 100 μL of 10% SDS, and the 
absorbance was taken at 570 nm [38].
3.2. Assays for apoptosis
Tali™ Image‐Based Apoptosis Kit utilizing Annexin V/propidium iodide (PI) binding was 
used to assess apoptotic cells (green fluorescence), dead cells (red and yellow fluorescence) 
and live cells (no fluorescence). The Tali™ Image‐Based Cytometer has two in‐built fluores-
cence channels: (1) green channel to measure V‐Alexa Fluor® 488, using 458‐nm excitation and 
525/20‐nm emission filters and (2) red channel to measure propidium iodide, using 530‐nm 
excitation and 585‐nm longpass emission filters. The alterations in permeability of mitochon-
drial membrane were studied using JC‐1 Mitochondrial Membrane Potential Kit (Abnova). 
All assays were performed according to the manufacturer's protocols. Spectral readout was 
done using Synergy H1 Multi‐Mode Microplate Reader (BioTek).
3.3. Real‐time PCR analysis
Total RNA was purified using the RNeasy Plus Mini Kit (Qiagen) containing g‐eliminator 
columns. Purity and quantification of products were tested through absorbance measure-
ments and gel imaging. RNAs of 1 μg were reverse transcribed to cDNAs using Transcriptor 
High Fidelity cDNA Synthesis Kit (Roche) according to the manufacturer's guidelines. Real‐
time PCR was applied using LightCycler 480 SYBR Green I Master Kit (Roche). Custom 
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plate involving primers for 16 genes of interest was designed and produced by Qiagen. Fold 
changes were evaluated through on‐site web application of the same company.
3.4. Western blot
Cells were lysed with 1× RIPA buffer (50 mM Tris‐HCl, pH 8.0, 150 mM NaCl, 1% NP40, 0.5% 
Na‐deoxycholate, 0.1% SDS) containing protease inhibitor cocktail (Complete, EDTA‐free 
Protease Inhibitor Cocktail Tablets, Roche) and 10 mM phosphatase inhibitor sodium fluo-
ride (Santa Cruz, SC‐24988B). Proteins of 40 μg were resolved by SDS‐PAGE and transferred 
to PVDF membranes. Membranes were incubated with primary and secondary antibodies 
after optimization. RNF7/SAG (Novus Biologicals, NBP1‐85594), survivin (Novus Biologicals, 
NB500‐201H) and phosphorylated Bad (pSer112) (Novus Biologicals, NB100‐81807) were poly-
clonal clones produced in rabbit. Beta‐actin (Novus Biologicals, NB600‐501) was monoclonal 
antibody produced in mouse. Detection was performed using chemiluminescent substrates 
for HRP (Western Bright ECL‐Advansta, K‐12045‐050) and Celvin S Chemiluminescence 
Imaging System (BioStep).
4. Results
4.1. Effects of etodolac on the proliferation of breast cancer cell cultures
The role of COX‐2 inhibitors in tumourigenesis was a focus of interest in recent years. The 
most commonly used, FDA‐approved, COX‐2 inhibitor in market is celecoxib. A recent 
study presented full effects of celecoxib both in vivo and in vitro on breast cancer cells [39]. 
Growth inhibitory effects of celecoxib were clearly observable between ranges 10 and 40 μM, 
especially after 72‐ and 96‐h incubations.
Etodolac is another approved COX‐2 inhibitor being used generally as adjuvant to chemo-
therapeutic applications. Early studies on etodolac were performed in colorectal cancers, 
and later it was tested in various other types such as liver, lung or prostate. In our study, 
cytotoxicity of etodolac was determined using MTT assay in two breast cancer cell lines, 
one of which is known for its good prognosis (MCF‐7) and the other for its malignant, 
invasive properties (MDA‐MB‐231). Proliferative effects of etodolac were insignificant at 
low concentrations (0–100 μM) in both cell lines. When concentrations were raised to 0.5 
or 1 mM, cell viability in both cell lines was considerably decreased (Figure 1A). Etodolac 
was less effective in MCF‐7, but there was a regular dose‐response relation in MDA‐MB‐231 
cells at the end of 48 h (Figure 1B). A good correlation was observed with the study where 
regular HT‐29 was compared with the invasive‐type colon cancer cell line HT‐29/Inv3 by 
Chen et al., where invasive type was found to be more susceptible to the effect of etodolac 
with a relative IC50 values of 0.5 versus 1.88 mM for other cell lines [40]. In our case, IC50 
value for MDA‐MB‐231 was found to be 0.69 mM, while no approximation was available 
for MCF‐7.
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4.2. Determination of apoptosis
There was no detectable apoptotic effect of etodolac at low doses, in accordance with our 
observations from MTT assays. When concentrations were raised to mM range, apoptosis 
was detectable through changes in mitochondrial membrane potential (Figure 2A). Apoptotic 
effect of etodolac was more prominent in MDA‐MB‐231 cells at the end of 48 h.
Apoptosis was further confirmed with Annexin V/PI staining using Tali™ Apoptosis Kit 
(Thermo Fisher Scientific) (Figure 2B).
4.3. Transcriptional profiling of apoptotic proteins of interest
To understand molecular mechanisms underlying observed apoptotic effects of etodolac and 
to clarify COX‐2 dependency of anti‐carcinogenic responses, regulatory changes in apoptotic 
pathways were investigated at molecular level. To achieve this, 105–106 cells were collected for 
Figure 2. Effect of etodolac on apoptosis in MCF‐7 and MDA‐MB‐231 cell lines. (A) The ratio of apoptotic to health cells 
at the end of 48‐h incubation period was quantified by JC‐1 staining with or without etodolac. (B) Apoptotic/dead cells 
were counted following Annexin V/PI staining using Tali™ Apoptosis Kit as described in Methods. Two‐way ANOVA 
was applied for each pair. *P < 0.05; **P < 0.01; ***P < 0.001.
Figure 1. Cell viability effect of etodolac on breast cancer cell lines. (A) Decrease in cell viability upon 0.5 and 1 mM 
etodolac addition. Each bar represents the mean ± SD of three independent experiments. Two‐way ANOVA was applied 
for each pair. *P < 0.05, ***P < 0.001. (B) Dose‐response curve for MCF‐7 and MDA‐MB‐231 cells treated with increasing 
concentration of etodolac (100, 250, 500, 750 and 1000 μM) for 48 h.
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real‐time and Western blot analyses as described in Section 3. Cell pellets were stored at −80°C 
to the day of experiments. Custom‐designed 96‐well‐plate‐containing primers for the genes of 
interest were purchased from Qiagen‐SAB Bioscience. Fold changes were calculated from Ct 
values, using delta‐delta Ct method. All values were normalized to GADPH expression and 
calculated with respect to non‐drugged controls (Table 1).
Genes over‐expressed in Genes under‐expressed in
Sample name Gene symbol (mM) Fold regulation* Sample name Gene symbol (mM) Fold regulation
24 h
MCF‐7 MCF‐7
BAD1 0.5 ++ BCL2L11 0.5 −
1 ++ 1 −
BAK1 0.5 + PMAIP1 0.5 −
1 +
BAX 0.5 ++ HIF1A 0.5 −
1 +
BID 0.5 + TP53 0.5 −
1 + 1 −
MB231
COX2 0.5 ++
1 +
ERBB2 0.5 ++
1 ++
BAX 0.5 +
1 +
BID 0.5 +
1 +
HIF1A 0.5 +
TP53 0.5 +
1 +
48 h
MCF‐7 MCF‐7
ERBB2 0.5 + BAD1 0.5 −
BAK1 0.5 −
MB231 BCL2L11 0.5 −
COX2 0.5 ++ BAX 1 −
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All analyses were made through Qiagen website facility provided for data analysis.
Etodolac induced an early increase in pro‐apoptotic proteins Bad1, Bak1, Bax and Bid gene 
expression, accompanied by Bcl‐2 down‐regulation for both concentrations in MCF‐7 cells. 
These changes were seen to decline as period was extended to 48 h. Another prompt response 
was the up‐regulation of HER‐2 and COX‐2 in MDA‐MB‐231 cells. There was a remarkable 
up‐regulation of anti‐apoptotic SAG protein after 48‐h incubation in MDA‐MB‐231 cells, par-
allel to BCL2L11 (Figure 3A and B).
4.4. Etodolac promoted anti‐apoptotic pathways in MDA‐MB‐231 cells
In translational level, phosphorylated form of Bad has slightly increased upon etodolac addi-
tion in MDA‐MB‐231 cells. SAG and survivin have also increased similarly in this cell line, in 
a dose‐ and time‐dependent manner (Figure 4A–C).
Low drug concentrations were also examined in long‐term culturing to see differences in rela-
tion to various dose‐time applications. Etodolac was added into cultures at 100 and 200 μM 
concentrations. Neither cell proliferation nor cell deaths were significantly affected under these 
concentrations (data not shown). Real‐time PCR analysis implicated that protein expressions 
were only moderately regulated in transcriptional level for all, except a consistent increase 
in anti‐apoptotic proteins, including SAG, in invasive MDA‐MB‐231 cells (Figure 5A and B).
Figure 3. Differential expression of 12 genes chosen in relation to COX‐2/apoptotic pathway. Fold changes were relative 
to control cells treated with DMSO after (A) 24 h and (B) 48 h. All expressions were normalized to GAPDH expression 
of corresponding cell line.
Genes over‐expressed in Genes under‐expressed in
Sample name Gene symbol (mM) Fold regulation* Sample name Gene symbol (mM) Fold regulation
ERBB2 0.5 ++ SAG 0.5 −
BCL2L11 0.5 ++ Survivin 0.5 −
SAG 0.5 ++ TP53 0.5 −
* + and − signs were used for up‐ and down‐regulations, respectively. Fold regulations >10 were signified using two marks.
Table 1. Fold changes after 24‐ and 48‐h incubation periods upon addition of 0.5 and 1 mM etodolac into cultures.
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Figure 4. Western blot analysis of anti‐apoptotic proteins (A) SAG at 24, 48 and 72 h, and (B) SAG and survivin after 48 h, 
together with (C) inactivated phosphorylated form of Bad. The data are representative of two independent experiments. 
Whole cell lysate was loaded as 40 μg proteins in each lane. β‐actin was used as house‐keeping control.
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Figure 5. Effect of 100 μM etodolac addition on gene expressions of 6 genes chosen in relation to COX‐2/apoptotic 
pathway after 72 and 96 h incubations. (A) Scattered plot analysis created by the software. The data points between the 
lines represent non‐regulated proteins with insignificant fold‐changes, where dots above the diagonals correspond to 
up‐ and dots below the diagonals correspond to down‐regulations respectively. (B) Bar graph of fold changes observed 
in MDA‐MB‐231 cells. Regulations in MCF‐7 cell line were minor, except negative regulation of BCL2L11, which 
correlated with positive regulations in Bak and Bax genes (data not shown).
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5. Discussion
The expression of COX‐1 and COX‐2 in breast cell line cultures was studied in an early report 
by Liu et al. [41]. The data revealed that COX‐2 is one of the markers showing differential 
expression between metastatic (MDA‐MB‐231) and non‐metastatic hormone‐responsive cell 
lines (MCF‐7). Metastatic cell line had clearly high constitutive expression of COX‐2 and a cor-
related increase in PGE2 levels. PGE2 production was firmly determined by phospholipase A2 
availability, which is known to be high in metastatic MDA‐MB‐231 cell line, and COX2 activ-
ity, that is also shown to be higher in this cell line. These findings were further confirmed by a 
later study comparing COX‐2 activity between colon cancer cell line HT‐29 and its metastatic 
variant HT‐29/Inv3 [40]. In prostate cancer cell lines, dose‐response relation was found to be 
weaker for etodolac compared to NS‐398, another selective COX‐2 inhibitor [11]. Strange find-
ing was that COX‐2 expression did not necessarily correlated with its activity and etodolac 
was able to suppress PGE2 and tumour invasiveness without effecting protein COX‐2 levels 
[14, 39]. Similarly, COX‐2 expression and apoptosis were examined in HT‐29 colon cancer 
cell lines, and high expression of COX‐2 was detected in HT‐29 cells with mutant APC. When 
full‐length wild‐type APC was expressed in the same line, the cell growth was declined and 
apoptosis was induced parallel to COX‐2 down‐regulation. However, activity tests showed 
that even though COX‐2 expression exists, it is catalytically inactive in these cells [9].
Following these reports, the role of COX‐2/PGE2 signalling in tumourigenesis, angiogenesis 
or suppression of apoptosis was further documented by many other studies and these fos-
tered new therapeutic approaches based on various selective coxib derivatives. Clinical appli-
cations, however, demonstrated that the usage of NSAIDs or in particular coxibs as promoting 
anti‐cancer agents has several drawbacks. Besides their serious side effects in gastrointestinal 
and cardiovascular systems, problems such as COX‐2‐independent anti‐carcinogenic effects, 
or interferences with other eicosanoid pathways, signifies that great caution should be taken 
in the clinical use of these drugs [42]. Therefore, assessment of molecular changes in detail 
under different conditions could provide valuable foresight for future applications.
Although quite complex, carcinogenesis involves several main routes to follow in cell trans-
formation. Limitless replicative capacity of cells could be a result of uncontrolled responses to 
growth signals, due to a constitutive receptor/ligand activity or insensitivity to growth signal 
inhibitors, cell cycle checkpoint defects, interfering with programmed cell death pathways, 
and sustained angiogenesis causing tumour invasion and metastasis.
Many signal transduction pathways cross talk and further complicate this picture. Studies 
focusing on cellular mechanisms of coxibs, in particular of etodolac and celecoxib, also reflect 
similar multi‐facet picture.
In light of these observations, proteins playing substantial role in apoptotic fate were investigated 
to better understand the relations between COX‐2/PGE2 and carcinogenesis. HER‐2 (ERBB‐2) 
and COX‐2 were utilized to verify the already‐identified correlation between high expression 
and invasiveness of the cells. As expected, MDA‐MB‐231 cells displayed higher expression levels 
of these genes and expressions were further up‐regulated upon etodolac addition. Even though 
etodolac is a known Cox‐2 inhibitor, as discussed above, its anti‐proliferative effects may be 
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Cox‐2 independent. A clinical study on breast cancers recently reported a significant increase in 
COX‐2 gene expression levels upon etodolac addition, correlated with cyclin D1 reduction [43].
Etodolac induced an early increase in Bad gene expression, accompanied by Bax up‐regula-
tion and Bcl‐2 down‐regulation in MCF‐7 cells, similar to the results previously reported for 
chemotherapeutic agents Taxol and Thiotepa [44]. Bad is able to regulate apoptosis by binding 
to the anti‐apoptotic Bcl‐2 family members Bcl‐2 or Bcl‐xL. This regulation proceeds post‐
translationally through modifications by kinases or phosphatases rather than transcriptional 
processes. Since only the unphosphorylated form of Bad is able to bind Bcl‐xL or Bcl‐2 to drive 
apoptotic process, we tested post‐translational modifications through Western blot analyses. 
Phosphorylated form of the protein was enriched not in MCF‐7 but in MDA‐MB‐231 cells. 
Phosphorylated form of Bad is inactive and explicitly induces growth and cancer develop-
ment. The relation between protein levels and development or progression of different cancer 
types, including breast cancer, was recently examined both in cancer cell lines and on large‐
scale clinical data collected from The Moffitt Cancer Center Total Cancer Care repository [45]. 
Our results, in agreement with these findings, confirm the role of Bad in breast cancer cells and 
exhibit antagonistic action of etodolac in two cell lines with benign and malign characteristics. 
Bad phosphorylation would be one effective point in metastatic behaviour of MDA‐MB‐231 
cell line. In addition to that, SAG and survivin were also clearly up‐regulated in MDA‐MB‐231. 
Strangely, SAG increment was prominent in cells treated with 100 μM etodolac for 72 h.
SAG/ROC/Rbx/Hrt, also known as RNF7, is a member of zinc RING finger gene family, first char-
acterized by Sun et al. [46]. This protein is a part of SCF E3 ubiquitin ligase complex and promotes 
polyubiquitination of various proteins involved in cell metabolism, signal transduction, cell cycle 
progression and apoptosis. Its reactive oxygen species (ROS)‐scavenging activity protects cells 
from apoptosis induced by mitogenic factors such as ROS, hypoxia, stress, radiation, and so on 
and promotes cell survival. SAG levels were found to be higher in malignant cells and indicated 
as a potential prognostic marker at several cancer types [47, 48]. We found a reverse correlation of 
SAG, Bcl‐xL and p53 expressions and overall survival of the advanced stage cervical carcinoma 
patients, as well as rectal cancer patients [49]. Apoptotic effects of SAG silencing were investigated 
in different cancer cell lines. Among the major pro‐apoptotic proteins (Bax, Bak, Puma, Bim, Bad 
and NOXA) and anti‐apoptotic proteins (Bcl‐2, Mcl‐1, survivin, XIAP, Bcl‐xL and cIAP2), only 
NOXA was substantially regulated [50]. Therefore, in addition to known apoptotic markers, such 
as Bcl‐2, Bax, Bak and Bad, we also wanted to examine if a potential association exists between 
SAG/NOXA‐ and COX‐2/PGE2‐related mechanisms leading to cell proliferation or apoptosis. As 
stated above, etodolac addition induced SAG up‐regulation in both high‐dose‐short‐time and 
low‐dose‐long‐time applications in invasive cell line MDA‐MB‐231. NOXA expression was in 
basal levels, but there was no detectable down‐regulation correlated with SAG levels.
In cancer, uncontrolled proliferation of cells leads to insufficient blood supply to the tissue, 
through the generation of aberrant microvessels. Lack of oxygen supply induces hypoxia‐
induced factor (HIF‐1), which in turn activates SAG and SAG drives HIF‐1α degradation 
through a feedback mechanism [51]. The role of hypoxia in the regulation of COX‐2, on the 
other hand, was found to be an up‐regulation of Cox‐2 protein levels and correlated with 
hypoxia‐inducible factor (HIF)‐1α induction. A feedback loop, similar to SAG turnover, was 
reported in COX‐2 pathway, in which COX‐2/PGE2 up‐regulation due to hypoxia enhances 
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HIF‐1α transcriptional activity and this reinforces COX‐2 up‐regulation through a feedback 
mechanism [52, 53]. BNIP3 was another protein we tested in our panel. BNIP3 is known to 
be activated by hypoxia, and this activation results in enhanced mitochondrial membrane 
permeability and apoptosis [54, 55]. There was no definite change in neither HIF‐1α nor 
BNIP3 levels (data not shown). In brief, among the sensitizers we tested (Bad, NOXA and 
BNIP3), only Bad was effectively regulated and etodolac does not show any straight regula-
tion on hypoxia‐related proteins. Our study marks the fact that in breast cancer, only the 
triple‐negative invasive cell line was responsive to the effects of etodolac. MDA‐MB‐231 
cell line promptly induced COX‐2/HER2 expressions upon etodolac addition. HIF‐1, BNIP3 
and TP53 up‐regulations in MDA‐MB‐231 were weak and these changes were reversing 
(down‐regulation) for MCF‐7 cells, but in similar levels. Up‐regulation of anti‐apoptotic pro-
teins (SAG, survivin and Bcl‐2) in MDA‐MB‐231 cell line was discernible in short times and 
became more evident when incubation time was extended to 3–4 days.
6. Conclusions
In this study, anti‐proliferative and apoptotic effects of etodolac were investigated in breast 
cancer cell lines, MCF‐7 and MDA‐MB‐231. Anti‐proliferative and apoptotic changes were 
found to be pronounced only after high concentrations. Cox‐2/HER2 over‐expression was con-
firmed in invasive cell line MDA‐MB‐231. Regulation of mitochondrial Bcl‐2 family proteins 
was moderate and pro‐ and anti‐apoptotic proteins showed similar but reverse distributions. 
However, there was a prompt transcriptional up‐regulation of Bad in MCF‐7 and a slower 
response in MDA‐MB‐231 cells as the accumulation of phosphorylated form of Bad, suggesting 
a prominent role for Bad‐mediated apoptotic pathway. In addition, SAG and survivin proteins 
increased in MDA‐MB‐231 cells in a dose‐time‐dependent manner. We believe that these find-
ings would be supportive for future studies targeting etodolac‐based therapies, as it reveals 
that apoptotic factors are differentially regulated in hormone‐responsive and invasive cell lines.
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